58 related articles for article (PubMed ID: 23397155)
1. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.
Gentile LF; Plitas G; Zabor EC; Stempel M; Morrow M; Barrio AV
Ann Surg Oncol; 2017 Dec; 24(13):3896-3902. PubMed ID: 28916978
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Bear HD; Tang G; Rastogi P; Geyer CE; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N
N Engl J Med; 2012 Jan; 366(4):310-20. PubMed ID: 22276821
[TBL] [Abstract][Full Text] [Related]
3. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
[TBL] [Abstract][Full Text] [Related]
4. Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer.
Chen W; Zhang J; Li F; Chen Z; Li J; Lu DL
World J Surg Oncol; 2024 May; 22(1):126. PubMed ID: 38725003
[TBL] [Abstract][Full Text] [Related]
5. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Kurian AW; Lichtensztajn DY; Keegan TH; Leung RW; Shema SJ; Hershman DL; Kushi LH; Habel LA; Kolevska T; Caan BJ; Gomez SL
Breast Cancer Res Treat; 2013 Jan; 137(1):247-60. PubMed ID: 23139057
[TBL] [Abstract][Full Text] [Related]
6. Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer.
Ryu HH; Ahn SH; Kim SO; Kim JE; Kim JS; Ahn JH; Jung KH; Kim SB; Ko BS; Lee JW; Son BH; Shin HJ; Kim HH; Gong GY; Kim HJ
Sci Rep; 2021 May; 11(1):10510. PubMed ID: 34006898
[TBL] [Abstract][Full Text] [Related]
7. Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
Rakha EA; Miligy IM; Quinn CM; Provenzano E; Shaaban AM; Marchiò C; Toss MS; Gallagy G; Murray C; Walshe J; Katayama A; Eldib K; Badr N; Tanchel B; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Ellis IO; Lee AHS
Br J Cancer; 2021 May; 124(11):1836-1842. PubMed ID: 33762723
[TBL] [Abstract][Full Text] [Related]
8. An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
Liang X; Li H; Coussy F; Callens C; Lerebours F
Chin J Cancer Res; 2019 Aug; 31(4):586-600. PubMed ID: 31564802
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
Ma X; Wang X; Huang J; Chen Y; Zhang J; Zhang B; Shi C; Liu L
PLoS One; 2016; 11(8):e0160148. PubMed ID: 27579484
[TBL] [Abstract][Full Text] [Related]
10. Use of bevacizumab as a first-line treatment for metastatic breast cancer.
Manso L; Moreno F; Márquez R; Castelo B; Arcediano A; Arroyo M; Ballesteros AI; Calvo I; Echarri MJ; Enrech S; Gómez A; González Del Val R; López-Miranda E; Martín-Angulo M; Martínez-Jañez N; Olier C; Zamora P
Curr Oncol; 2015 Apr; 22(2):e51-60. PubMed ID: 25908921
[TBL] [Abstract][Full Text] [Related]
11. G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?
Rodrigues-Ferreira S; Nahmias C
Front Pharmacol; 2015; 6():24. PubMed ID: 25741281
[TBL] [Abstract][Full Text] [Related]
12. Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.
Paulmurugan R; Oronsky B; Brouse CF; Reid T; Knox S; Scicinski J
Theranostics; 2013; 3(6):437-47. PubMed ID: 23781290
[TBL] [Abstract][Full Text] [Related]
13. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
16. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
17. The role of targeted therapy and biomarkers in breast cancer treatment.
Stopeck AT; Brown-Glaberman U; Wong HY; Park BH; Barnato SE; Gradishar WJ; Hudis CA; Rugo HS
Clin Exp Metastasis; 2012 Oct; 29(7):807-19. PubMed ID: 22692561
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
Sánchez-Rovira P; Seguí MA; Llombart A; Aranda E; Antón A; Sánchez A; Lomas M; Jaén A; Fernández M; Porras I; Dalmau E; Morales S; de la Haba-Rodríguez J
Clin Transl Oncol; 2013 Oct; 15(10):810-7. PubMed ID: 23397155
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
